
Get full access for you and your coworkers.
Start a free company trial todayAlready a member? Log in.
Monday's announcement that Orphazyme's main candidate, arimoclomol, for treating degenerative muscle disease IBM has not met its effect targets is highly disappointing and surprising, says the firm's CFO. Now, the company considers scaling back its efforts in the area.
Already a member? Log in.